The continuing challenge of ocular leprosy
The timely resurgence of interest in ocular leprosy noted in this journal a year ago continues,' as witnessed by the number of clinical papers from various centres which have recently appeared in the ophthalmic literature and the emphasis that is now being placed on measures for the prevention of blindness. 2 Apart from being one of the oldest infections known to man, leprosy is still the systemic disease with the highest incidence of ocular complications. Epidemiological studies of these have always proved to be difficult to obtain, and estimates of important aspects of the disease such as blindness rates and the prevalence of sight threatening lesions may fall wide of the mark. 3 Ocular involvement in leprosy depends on a number of internal and external factors which may vary, not just within ethnic groups and geographic regions, but also from community to community. These factors include such variables as the age, race, and sex of the individual, the type of leprosy, its duration, therapy, and status. To these must be added the influence that the climate, environment, occupation, and social status have on the disease, and, most important of all, what measures to prevent eye complications are undertaken locally. Ocular leprosy is after all the archetypal preventive disease, and simple treatment at an early stage will usually avoid major irreversible damage later. This will be reflected by blindness and disability rates from different centres. Indeed, analysis of data derived from regional studies on the prevalence of eye complications often gives a very good idea of what services for leprosy are available in the community and how effective they are.
The problems of gathering information on the prevalence of eye complications in leprosy are further hindered by difficulties in estimating the actual numbers of patients with the disease. Many affected individuals do not come forward for treatment and therefore do not appear on registers until quite late in the course of disease. This is often due to ignorance, or it may reflect the social stigma that still exists throughout the world. The figures are further distorted by the WHO policy of deregistering patients once they have completed multidrug therapy and have satisfied the criteria for cure -a policy that has many pitfalls from the ophthalmic point of view. It is not therefore difficult to see why hard epidemiological data on the prevalence of ocular complications of leprosy are scarce, and knowledge on their incidence is almost non-existent.
A large multicentred study of ocular involvement in the disease, which included information on more than 3000 patients obtained by simple standardised examination techniques from over 30 centres in the world, showed that 5-5% of patients examined had bilateral corrected vision of less than 3/60 and were therefore blind by WHO definition, and 7 0% had vision less than 6/60, classified as having severe visual impairment. The same study demonstrated that 21-3% of patients had potentially sight-threatening lesions, defined as conditions likely to lead to visual loss unless preventive treatment was instituted.4 A parallel study on 354 patients who had been discharged from care having completed multidrug therapy, showed a prevalence of 24-3% with potentially sight-threatening lesions,5 and this raises the important point that in a considerable number of patients 'cure', as defined by the WHO, does not guarantee freedom from eye complications, and many patients may face increasing ocular problems unless they are adequately supervised by leprologists after completing therapy.
Epidemiological information is therefore still lacking. But, if the global leprosy population is taken to be between 10 and 12 million,6 the disease ranks as one of the major causes of world blindness, likely to increase proportionally as others such as trachoma, xerophthalmia, and onchocerciasis become contained by modern therapy and public health measures.
The numbers, however, do not give the whole story. Leprosy is a unique condition, not least because of its social stigma, which evokes almost mediaeval sentiments in many countries, condemning the patient to become a member of one of the most disadvantaged groups in society. It is also a crippling disease. The nerve damage which is a feature of all forms of the condition, but particularly affects multibacillary (MB) patients, destroys tactile sensation, decreases mobility, and causes the familiar skeletal deformities. Loss of vision in these patients is a major event in this downward sequence of disability and frequently renders the patient entirely dependent on others. 'Blindness in the individual who has normal skin sensitivity is enough of a handicap, but in one who has lost that faculty it is disastrous. Few 
